AstraZeneca fulfils commitment to deliver 6.4 million COVID-19 vaccine doses to Malaysia

AstraZeneca today delivered a further 1,365,200 doses of COVID-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]) to Malaysia, marking the successful completion of its commitment to supply 6.4 million doses under the Advanced Purchase Agreement with the Malaysian government.

To date, more than 9.2 million doses of AstraZeneca’s vaccine have been delivered to Malaysia through direct supply, COVAX, and donations from other countries, in support of the country's vaccination programme.

Dr Sanjeev Panchal, Country President, AstraZeneca Malaysia said: “AstraZeneca is committed to our role of delivering vaccine doses that reduce hospitalisations and save lives. Given the emergence of Omicron and the dynamic challenges presented by the virus, we will continue to support the government and the people throughout the changing course of the pandemic.”

AstraZeneca has supplied over 2.5 billion doses of COVID-19 Vaccine AstraZeneca to over 170 countries. Approximately two-thirds of doses have gone to low- and lower-middle-income countries.

COVID-19 Vaccine AstraZeneca
COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was invented by the University of Oxford. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

The vaccine has been granted a conditional marketing authorisation or emergency use in more than 90 countries. It also has Emergency Use Listing from the World Health Organization, which accelerates the pathway to access in up to 144 countries through the COVAX Facility.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca

For further details, please contact

Approval code: MY_AZ_MY-8379_07/02/2022